
The study demonstrates that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue. GALNT7 can identify men with prostate cancer, using urine and blood samples, with improved diagnostic accuracy than serum PSA alone. GALNT7 levels remain high in progression to castrate-resistant disease, and using in vitro and in vivo models, reveals that GALNT7 promotes prostate tumour growth. Mechanistically, GALNT7 can modify O-glycosylation in prostate cancer cells and correlates with cell cycle and immune signalling pathways. This study provides a new biomarker to aid the diagnosis of clinically significant disease and cements GALNT7-mediated O-glycosylation as an important driver of prostate cancer progression.
Like
Save
Share